Review
Assessing health economic outcome in Alzheimer's disease clinical trials
Affiliations
- PMID: 17653498
Item in Clipboard
Review
Assessing health economic outcome in Alzheimer's disease clinical trials
J Nutr Health Aging.
2007 Jul-Aug.
Abstract
This paper reviews methodological considerations in collecting data on economic endpoints and conducting economic evaluation alongside clinical trials in Alzheimer's disease (AD).
Similar articles
-
Issues in the economic evaluation of treatment for dementia. Position paper from the International Working Group on Harmonization of Dementia Drug Guidelines.Alzheimer Dis Assoc Disord. 1997;11 Suppl 3:39-45. Alzheimer Dis Assoc Disord. 1997. PMID: 9305515 No abstract available.
-
Modelling the clinical and economic implications of galantamine in the treatment of mild-to-moderate Alzheimer's disease in Germany.J Med Econ. 2010;13(4):641-54. doi: 10.3111/13696998.2010.528101. Epub 2010 Oct 19. J Med Econ. 2010. PMID: 20958114
-
Cost-effectiveness analysis of donepezil for mild to moderate Alzheimer's disease in Taiwan.Int J Geriatr Psychiatry. 2008 Jan;23(1):73-8. doi: 10.1002/gps.1842. Int J Geriatr Psychiatry. 2008. PMID: 17520661
-
[Therapeutic results: tacrine].Rev Med Brux. 1997 Dec;18(6):394-7. Rev Med Brux. 1997. PMID: 9481161 Review. French.
-
Scales as outcome measures for Alzheimer's disease.Alzheimers Dement. 2009 Jul;5(4):324-39. doi: 10.1016/j.jalz.2009.05.667. Alzheimers Dement. 2009. PMID: 19560103
Cited by
-
Disease progression and costs of care in Alzheimer's disease patients treated with donepezil: a longitudinal naturalistic cohort.Eur J Health Econ. 2012 Oct;13(5):561-8. doi: 10.1007/s10198-011-0334-y. Epub 2011 Aug 6. Eur J Health Econ. 2012. PMID: 21822729
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical